Koen Vos

3.8k citations

37 papers · 2.9k · 2 hit papers · h-index 24

Impact in

Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Parasitology top 1%
- Vector-borne infectious diseases

Papers in

Rheumatology 28
- Rheumatoid Arthritis Research and Therapies 25
- Systemic Lupus Erythematosus Research 17
Radiology, Nuclear Medicine and Imaging 15
- Monoclonal and Polyclonal Antibodies Research 14

Co-authors: Rogier M. Thurlings (13 shared papers)Henk Visser (3 shared papers)Ferdinand C. Breedveld (3 shared papers)Saskia le Cessie (2 shared papers)Johanna M. W. Hazes (1 shared paper)Paul P. Tak (14 shared papers)Daniëlle M. Gerlag (13 shared papers)A. H. Zwinderman (4 shared papers)
Journals: Annals of the Rheumatic Diseases (12 papers)Lara D. Veeken (2 papers)Clinical Infectious Diseases (1 paper)Atherosclerosis (1 paper)Journal of Clinical Microbiology (1 paper)
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Koen Vos

36 papers receiving 2.8k citations

Koen Vos's Hit Papers

align trajectories log scale

How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis 2002 · 551 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 Arthritis & Rheumatism
1993 Clinical Infectious Diseases

Peers

Countries citing papers authored by Koen Vos

Since Specialization

Citations

This map shows the geographic impact of Koen Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koen Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koen Vos more than expected).

Fields of papers citing papers by Koen Vos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koen Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koen Vos. The network helps show where Koen Vos may publish in the future.

Co-authors

The 25 scholars most cited alongside Koen Vos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Koen Vos Line = papers co-authored together Koen Vos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis Arthritis & Rheumatism ·Henk Visser, Saskia le Cessie, Koen Vos, Ferdinand C. Breedveld, Johanna M. W. Hazes Hit paper breakdown →	2002	551
2	Different Genospecies of Borrelia burgdorferi Are Associated with Distinct Clinical Manifestations of Lyme Borreliosis Clinical Infectious Diseases ·Alje P. van Dam, H. Kuiper, Koen Vos, A Widjojokusumo, B. M. de Jongh, Lodewijk Spanjaard, A. C. P. Ramselaar, Michael D. Kramer, J. Dankert Hit paper breakdown →	1993	455
3	Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response Annals of the Rheumatic Diseases ·Rogier M. Thurlings, Koen Vos, C A Wijbrandts, A. H. Zwinderman, D M Gerlag, PP Tak	2007	254
4	Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis Arthritis & Rheumatism ·Koen Vos, Rogier M. Thurlings, Carla A. Wijbrandts, Dirkjan van Schaardenburg, Daniëlle M. Gerlag, Paul P. Tak	2007	144
5	The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor Î± expression in the synovium Annals of the Rheumatic Diseases ·C A Wijbrandts, M.G.W. Dijkgraaf, Maarten C. Kraan, Marjolein Vinkenoog, Tom Smeets, Huibert J. Dinant, Koen Vos, Willem F. Lems, Gertjan Wolbink, D Sijpkens, B. A. C. Dijkmans, Paul P. Tak	2007	113
6	DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis Annals of the Rheumatic Diseases ·Y P M Goekoop-Ruiterman, Jeska K de Vries‐Bouwstra, P. J. S. M. Kerstens, M. Nielen, Koen Vos, Dirkjan van Schaardenburg, I. Speyer, Patrick Seys, F. C. Breedveld, Cornelia F Allaart, Ben A. C. Dijkmans	2009	102
7	Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients Arthritis & Rheumatism ·Rogier M. Thurlings, Marie Boumans, Janneke Tekstra, J.A. van Roon, Koen Vos, Daisy Marie van Westing, Lisa G. M. van Baarsen, Carina L. Bos, Kyriakos A. Kirou, Daniëlle M. Gerlag, Mary K. Crow, J. W. J. Bijlsma, Cornelis L. Verweij, Paul P. Tak	2010	100
8	Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers The Journal of Rheumatology ·Barry Bresnihan, Eliza Pontifex, Rogier M. Thurlings, Marjolein Vinkenoog, Hani El‐Gabalawy, Ursula Fearon, Oliver FitzGerald, Daniëlle M. Gerlag, Terence Rooney, Marleen G. van de Sande, Douglas J. Veale, Koen Vos, Paul‐Peter Tak	2009	97
9	Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Annals of the Rheumatic Diseases ·Koen Vos, Peter G. A. Steenbakkers, Amm Miltenburg, Ebo Bos, MW van den Heuvel, R. van Hogezand, de Rivka Vries, FC Breedveld, Annemieke M. H. Boots	2000	97
10	Long‐term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12‐year followup Arthritis Care & Research ·K.W. Drossaers-Bakker, A. H. Zwinderman, T. P. M. Vliet Vlieland, D. van Zeben, Koen Vos, F. C. Breedveld, J. M. W. Hazes	2002	91
11	Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·Rogier M. Thurlings, O. Teng, Koen Vos, Daniëlle M. Gerlag, L Aarden, Steven O. Stapel, Jacob M. van Laar, Paul P. Tak, Gertjan Wolbink	2009	89
12	Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis Atherosclerosis ·Aart C. Strang, Radjesh J. Bisoendial, Ruud S. Kootte, Dominik M. Schulte, Geesje M. Dallinga‐Thie, J.H.M. Levels, Marc R. Kok, Koen Vos, Sander W. Tas, Uwe J.F. Tietge, Nike Müller, Matthias Laudes, Daniëlle M. Gerlag, Erik S.G. Stroes, Paul P. Tak	2013	81
13	A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue Annals of the Rheumatic Diseases ·Arno W. R. van Kuijk, Daniëlle M. Gerlag, Koen Vos, Gertjan Wolbink, M. de Groot, Menno A. de Rie, A. H. Zwinderman, Ben A. C. Dijkmans, Paul P. Tak	2008	76
14	Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity Annals of the Rheumatic Diseases ·Tom Groot Kormelink, Janneke Tekstra, Rogier M. Thurlings, M H J Boumans, Koen Vos, Paul P. Tak, J. W. J. Bijlsma, F.P. Lafeber, Frank A. Redegeld, J. A. G. van Roon	2010	59
15	Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage Arthritis & Rheumatism ·Leroy R. Lard, Maarten Boers, Arco C. Verhoeven, Koen Vos, Henk Visser, J. M. W. Hazes, A. H. Zwinderman, G. M. T. Schreuder, FC Breedveld, René R. P. de Vries, S van der Linden, Eric Zanelli, T. Huizinga	2002	57
16	Disease activity–guided rituximab therapy in rheumatoid arthritis: The effects of re‐treatment in initial nonresponders versus initial responders Arthritis & Rheumatism ·Rogier M. Thurlings, Koen Vos, Daniëlle M. Gerlag, Paul P. Tak	2008	55
17	Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis Annals of the Rheumatic Diseases ·Maria J H Boumans, Rogier M. Thurlings, Lorraine Yeo, Dagmar Scheel‐Toellner, Koen Vos, Daniëlle M. Gerlag, Paul P. Tak	2011	52
18	Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis Annals of the Rheumatic Diseases ·Jacqueline E Paramarta, Leen De Rycke, Tanja F Heijda, Carmen A. Ambarus, Koen Vos, Huib J. Dinant, Paul P. Tak, Dominique Baeten	2012	51
19	Association of the –2849 interleukin‐10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis Arthritis & Rheumatism ·Leroy R. Lard, F. A. van Gaalen, Joris Schonkeren, Elsbet Pieterman, Gerrie Stoeken, Koen Vos, Rob G. H. H. Nelissen, Rudi G. J. Westendorp, Rob C. Hoeben, FC Breedveld, René E. M. Toes, T. Huizinga	2003	49
20	Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis Journal of Clinical Microbiology ·H. Kuiper, Alje P. van Dam, Lodewijk Spanjaard, B. M. de Jongh, A Widjojokusumo, T C Ramselaar, Irina Cairo, Koen Vos, J. Dankert	1994	39

About Koen Vos

Koen Vos is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging, Immunology, Genetics and Pathology and Forensic Medicine, having authored 37 papers that have together received 2.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (25 papers), Systemic Lupus Erythematosus Research (17 papers), Monoclonal and Polyclonal Antibodies Research (14 papers), T-cell and B-cell Immunology (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Autoimmune and Inflammatory Disorders Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Vector-borne infectious diseases (4 papers). The work is most often cited by research in Rheumatology (1.7k citations), Parasitology (518 citations), Hematology (469 citations), Immunology (731 citations) and Genetics (315 citations). Koen Vos has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Rogier M. Thurlings, Henk Visser, Ferdinand C. Breedveld, Saskia le Cessie, Johanna M. W. Hazes, Paul P. Tak, Daniëlle M. Gerlag, A. H. Zwinderman, J. Dankert and B. M. de Jongh. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Clinical Infectious Diseases, Atherosclerosis and Journal of Clinical Microbiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Koen Vos

Impact in

Papers in i

In The Last Decade

Koen Vos

Koen Vos's Hit Papers

Peers

Countries citing papers authored by Koen Vos

Fields of papers citing papers by Koen Vos

All Works

About Koen Vos

Explore authors with similar magnitude of impact

Papers in